Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 11/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7536103 | 0.85 | PKM (0.57) | PKMTP53LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7543069 | 0.84 | PKM (0.44) | PKMTP53LMNASMN1; SMN2MAPK1 | |
| SCHEMBL7541742 | 0.83 | PKM (0.60) | PKMTP53LMNASMN1; SMN2HTT | |
| SCHEMBL7539142 | 0.82 | PKM (0.77) | PKMTP53LMNASMN1; SMN2MAPK1 | |
| SCHEMBL7536210 | 0.78 | PKM (0.54) | PKMTP53LMNASMN1; SMN2MAPK1 | |
| SCHEMBL7503536 | 0.72 | PKM (0.61) | PKMTP53LMNASMN1; SMN2MAPK1 | |
| SCHEMBL7536037 | 0.71 | PKM (0.55) | PKMTP53LMNASMN1; SMN2MAPK1 | |
| SCHEMBL18306665 | 0.71 | PKM (0.53) | PKMTP53LMNASMN1; SMN2MAPK1 | |
| SCHEMBL7541421 | 0.71 | PKM (0.82) | PKMTP53LMNASMN1; SMN2MAPK1 | |
| SCHEMBL7537514 | 0.70 | EGFR (0.49) | PKMTP53LMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007608-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | AGIOS PHARMACEUTICALS INC (US) | 2017-01-12 | — | — | US | disclosed |
| EP-2427441-B1 | PKM2 ACTIVATORS FOR USE IN THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20140249150-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | AGIOS PHARMACEUTICALS, INC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8501953-B2 | PKM2 modulators for use in the treatment of cancer | AGIOS PHARMACEUTICALS, INC (US) | 2013-08-06 | — | — | US | disclosed |
| WO-2013056153-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | KUNG CHARLES (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20120122849-A1 | PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| WO-2010129596-A1 | PMK2 MODULATORS FOR USE IN THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122849-A1 | PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER | PDK2, PDK1, PDK3 | PKM 5/4885TP53 302/4885LMNA 2326/4885 |
| US-20140249150-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | PDK1, PC, PDK2 | PKM 11/4885TP53 722/4885LMNA 863/4885 |
| US-20170007608-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | PDK1, PC, PDK2 | PKM 11/4885TP53 722/4885LMNA 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.